MedTrace Logo

Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

NCT02470403 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

A 12-week study to assess LIK066 effect on body weight in diabetics, prediabetics and normoglycemic patients with elevated body mass index (BMI)

Conditions

  • Elevated Body Mass Index

Interventions

DRUG

LIK066

LIK066 25 mg tablets

DRUG

Placebo

Matching placebo tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-05
Primary Completion
2016-04-04
Completion
2016-04-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02470403 on ClinicalTrials.gov